ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin

NCT06521190 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cisplatin-induced Hearing Loss

Interventions

DRUG: ACOU085 (bimokalner)
DRUG: Placebo

Sponsor

Acousia Therapeutics GmbH